Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Philippe Moreau, Meletios Α. Dimopoulos et al.|New England Journal of Medicine|2023Cited by 538
Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and CyclophosphamideMeletios Α. Dimopoulos, Gerasimos Pangalis, Souzana Delimpasi et al.|Journal of Clinical Oncology|2007Cited by 279
Natural History of Osteonecrosis of the Jaw in Patients With Multiple MyelomaAshraf Badros, Meletios Α. Dimopoulos, Evangelos Terpos et al.|Journal of Clinical Oncology|2008Cited by 145
The <scp>C</scp>hronic <scp>K</scp>idney <scp>D</scp>isease <scp>E</scp>pidemiology <scp>C</scp>ollaboration cystatin <scp>C</scp> (<scp>CKD</scp>‐<scp>EPI</scp>‐<scp>C</scp>ys<scp>C</scp>) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from <scp>MDRD</scp> to <scp>CKD</scp>‐<scp>EPI</scp>‐<scp>C</scp>ys<scp>C</scp> equations?Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis et al.|European Journal Of Haematology|2013Cited by 46
Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent eraMeletios Α. Dimopoulos, Efstathios Kastritis, Sossana Delimpasi et al.|European Journal Of Haematology|2012Cited by 37